Page 39 - AN-4-2

Advanced Neurology SARS-CoV-2 mechanisms of neurological impact

doi: 10.1056/NEJMc2033369 sequelae of severe acute respiratory syndrome coronavirus 2
infection. J Infect Dis. 2021;224(11):1839‑1848.
92. Bulfamante G, Chiumello D, Canevini MP, et al. First
ultrastructural autoptic findings of SARS -Cov-2 in doi: 10.1093/infdis/jiab490
olfactory pathways and brainstem. Minerva Anestesiol.
2020;86(6):678‑679. 103. Tansey MG, Wallings RL, Houser MC, Herrick MK,
Keating CE, Joers V. Inflammation and immune
doi: 10.23736/S0375-9393.20.14772-2 dysfunction in Parkinson disease. Nat Rev Immunol.
93. Paniz-Mondolfi A, Bryce C, Grimes Z, et al. Central nervous 2022;22(11):657‑673.
system involvement by severe acute respiratory syndrome doi: 10.1038/s41577-022-00684-6
coronavirus-2 (SARS-CoV-2). J Med Virol. 2020;92(7):699‑702.
104. Group RC. Tocilizumab in patients admitted to hospital with
doi: 10.1002/jmv.25915 COVID-19 (RECOVERY): A randomised, controlled, open-
94. Eden A, Kanberg N, Gostner J, et al. CSF biomarkers in label, platform trial. Lancet. 2021;397(10285):1637‑1645.
patients with COVID-19 and neurologic symptoms: A case doi: 10.1016/S0140-6736(21)00676-0
series. Neurology. 2021;96(2):e294‑e300.
105. Singal CMS, Jaiswal P, Seth P. SARS-CoV-2, More than a
doi: 10.1212/WNL.0000000000010977 respiratory virus: Its potential role in neuropathogenesis.
95. Heming M, Li X, Rauber S, et al. Neurological manifestations ACS Chem Neurosci. 2020;11(13):1887‑1899.
of COVID-19 feature T cell exhaustion and dedifferentiated doi: 10.1021/acschemneuro.0c00251
monocytes in cerebrospinal fluid. Immunity. 2021;54(1):164‑
175.e6. 106. Groppa S, Gonzalez-Escamilla G, Eshaghi A, Meuth
SG, Ciccarelli O. Linking immune-mediated damage to
doi: 10.1016/j.immuni.2020.12.011 neurodegeneration in multiple sclerosis: Could network-
96. Yong SJ. Persistent brainstem dysfunction in long-COVID: based MRI help? Brain Commun. 2021;3(4):fcab237.
A hypothesis. ACS Chem Neurosci. 2021;12(4):573‑580. doi: 10.1093/braincomms/fcab237
doi: 10.1021/acschemneuro.0c00793 107. Etemadifar M, Abhari AP, Nouri H, et al. Does COVID-19
97. Mina Y, Enose-Akahata Y, Hammoud DA, et al. Deep increase the long-term relapsing-remitting multiple sclerosis
phenotyping of neurologic postacute sequelae of SARS- clinical activity? A cohort study. BMC Neurol. 2022;22(1):64.
CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. doi: 10.1186/s12883-022-02590-9
2023;10(4):e200097.
108. Zenesini C, Vignatelli L, Belotti LMB, et al. Risk of SARS-
doi: 10.1212/NXI.0000000000200097 CoV-2 infection, hospitalization and death for COVID-
98. Mohlendick B, Schonfelder K, Breuckmann K, et al. ACE2 19 in people with Parkinson’s disease or parkinsonism
polymorphism and susceptibility for SARS-CoV-2 infection over a 15-month period: A cohort study. Eur J Neurol.
and severity of COVID-19. Pharmacogenet Genomics. 2022; 29(11):3205‑3217.
2021;31(8):165‑171. doi: 10.1111/ene.15505
doi: 10.1097/FPC.0000000000000436 109. Del Prete E, Francesconi A, Palermo G, et al. Prevalence
99. Maglietta G, Diodati F, Puntoni M, et al. Prognostic factors and impact of COVID-19 in Parkinson’s disease: Evidence
for post-COVID-19 syndrome: A systematic review and from a multi-center survey in Tuscany region. J Neurol.
meta-analysis. J Clin Med. 2022;11(6):1541. 2021;268(4):1179‑1187.
doi: 10.3390/jcm11061541 doi: 10.1007/s00415-020-10002-6
100. Fernandez-de-Las-Penas C, Arendt-Nielsen L, Diaz-Gil G, et al. 110. Putri C, Hariyanto TI, Hananto JE, Christian K,
Genetic association between ACE2 (rs2285666 and rs2074192) Situmeang RFV, Kurniawan A. Parkinson’s disease
and TMPRSS2 (rs12329760 and rs2070788) polymorphisms may worsen outcomes from coronavirus disease 2019
with post-COVID symptoms in previously hospitalized (COVID-19) pneumonia in hospitalized patients:
COVID-19 survivors. Genes (Basel). 2022;13(11):1935. A systematic review, meta-analysis, and meta-regression.
Parkinsonism Relat Disord. 2021;87:155‑161.
doi: 10.3390/genes13111935
doi: 10.1016/j.parkreldis.2021.04.019
101. Andrews MG, Mukhtar T, Eze UC, et al. Tropism of SARS-
CoV-2 for human cortical astrocytes. Proc Natl Acad Sci U S 111. Ferini-Strambi L, Salsone M. COVID-19 and neurological
A. 2022;119(30):e2122236119. disorders: Are neurodegenerative or neuroimmunological
doi: 10.1073/pnas.2122236119 diseases more vulnerable? J Neurol. 2021;268(2):409‑419.
102. Peluso MJ, Lu S, Tang AF, et al. Markers of immune doi: 10.1007/s00415-020-10070-8
activation and inflammation in individuals with postacute 112. Szabo MP, Iba M, Nath A, Masliah E, Kim C. Does SARS-

Volume 4 Issue 2 (2025) 33 doi: 10.36922/an.4909